FINWIRES · TerminalLIVE
FINWIRES

Gold X2 Mining Gets NYSE American Listing Approval and Extension of Deadline for AGM

By

Gold X2 Mining's (AUXX.V) shares have been approved for listing on the NYSE American LLC, and are expected to start trading on the NYSE American under symbol AUXX on Sept. 8, or as soon as permitted, it said Wednesday.

The shares will stop trading on the OTCQB once trading begins on the NYSE American, said the company.

The company's shares will continue trading under ticker symbol AUXX on the TSX Venture Exchange, it added.

Additionally, the company is now required to hold its annual general meeting of shareholders for 2026 by Jan. 26, 2027, as the British Columbia Registrar of Companies and the TSXV granted it an extension to hold its AGM, which it was originally required to hold by Sept. 26, 2026, added Gold X2 Mining.

"Access to the world's largest and most liquid equity market is expected to significantly enhance our exposure to U.S. institutional and retail investors while providing a stronger platform to unlock the value of the Moss Gold Project," said Chief Executive Officer Michael Henrichsen.

Related Articles

Mining & Metals

Alimentation Couche-Tard Q1 Adjusted EPS Rises to $0.90; Revenue Beats FactSet Estimate

Alimentation Couche-Tard (ATD.TO) said after the close Tuesday its fiscal first-quarter adjusted earnings per share rose to $0.90 from $0.78 in the prior-year period.Revenue for the period ended July 19 increased to $21.70 billion in the quarter ended July 19 from $17.35 billion a year earlier, exceeding the FactSet consensus estimate of $20.86 billion.The company also declared a quarterly dividend of C$0.22 per share for the first quarter of fiscal 2027, payable Sept. 25 to shareholders of record as of Sept. 11.Shares of the company closed up C$0.81 to C$84.28 on Toronto Stock Exchange.

$ATD.TO
Mining & Metals

Hammond Power Solutions Hikes Its Quarterly Dividend 5.5% to C$0.29 per Class B Share. The Higher Dividend Will Be Paid Sept. 24 to Shareholders of Record on Sept. 17

$HPS-A.TO
Mining & Metals

Cipher Pharmaceuticals' Ownership Of Certain Abscoria-Related Clinical Data Affirmed by US Court

Cipher Pharmaceuticals (CPH.TO) said Tuesday after trade that a New York federal court denied Sun Pharmaceuticals' petition to vacate an arbitrator's ruling concerning the ownership of certain clinical data.The court agreed with the arbitrator that Cipher owned clinical data that was used by Sun to launch a prescription anti-acne medication, Abscoria, in Canada in 2023.The arbitrator had awarded Cipher damages of C$4.2 million, a 15% royalty on net sales of Absorica in Canada from Jan. 1, 2026, and ending on Dec. 31, 2040. Also awarded was 80% of Cipher's out-of-pocket attorneys' fees and certain expenses related to the arbitration process, a statement said.The federal court awarded Cipher interest on the damages and its out-of-pocket attorneys' fees and certain expenses directly related to the arbitration process, at a rate of 9% per annum.Cipher Pharmaceuticals shares closed up C$0.51 at C$14.19 on the Toronto Stock Exchange.

$CPH.TO